Enterprise Value

32.81B

Cash

889M

Avg Qtr Burn

N/A

Short % of Float

0.04%

Insider Ownership

0.13%

Institutional Own.

8.77%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ORPATHYS (Savolitinib) (C-MET inhibitor) Details
Non-small cell lung carcinoma, Cancer, Colorectal cancer , Renal cell carcinoma, Gastric cancer

Approved

Quarterly sales

ELUNATE (Fruquintinib) (VEGFR 1/2/3) Details
Metastatic colorectal cancer, Colorectal cancer , Non-small cell lung carcinoma, Solid tumor/s, Cancer

Approved

Quarterly sales

ELUNATE (Fruquintinib) + paclitaxel Details
Cancer, Solid tumor/s, Gastroesophageal adenocarcinomas, Gastric cancer

NDA

Acceptance for review

ORPATHYS (Savolitinib) (C-MET inhibitor) Details
Renal cell carcinoma, Cancer, Gastric cancer

Phase 3

Data readout

ORPATHYS (Savolitinib) + TAGRISSO Details
Cancer, Non-small cell lung carcinoma

Phase 3

Data readout

HMPL-306 Details
Hematologic malignancies, Blood cancer, Acute myeloid leukemia

Phase 3

Data readout

Phase 3

Data readout

SULANDA (Surufatinib) Details
Solid tumor/s, Neuroendocrine tumor, Pancreatic cancer, Cholangiocarcinoma, Cancer

Phase 3

Update

SULANDA (Surufatinib) + Camrelizumab Details
Solid tumor/s, Pancreatic cancer, Cancer, Pancreatic ductal adenocarcinoma

Phase 2/3

Data readout

Sovleplenib (HMPL-523) (Syk inhibitor) Details
Warm autoimmune hemolytic anemia

Phase 2/3

Data readout

ELUNATE (Fruquintinib) + Sintilimab Details
Renal cell carcinoma, Cancer, Solid tumor/s, Kidney cancer

Phase 2/3

Data readout

Tazemetostat Details
Follicular lymphoma

Phase 2

Data readout

HMPL-453 (FGFR 1/2/3) Details
Mesothelioma, Intrahepatic cholangiocarcinoma , Cancer

Phase 2

Update

Phase 2

Update

ELUNATE (Fruquintinib) + Sintilimab Details
Solid tumor/s, Endometrial cancer, Cancer

Phase 1/2

Data readout

Sovleplenib (HMPL-523) (Syk inhibitor) Details
Warm autoimmune hemolytic anemia

Phase 1/2

Update

Phase 1/2

Initiation

HMPL-506 Details
Cancer, Leukemia

Phase 1

Initiation